ALDX — Aldeyra Therapeutics Share News
0.000.00%
Last trade - 00:00Brief: Aldeyra Therapeutics Completes Enrollment In Phase 3 Clinical Trial Of Reproxalap In Dry Eye Disease
Aldeyra Therapeutics Inc expected to post a loss of 11 cents a share - Earnings Preview
U.S. STOCKS ON THE MOVE-Identiv, Levi Strauss, cannabis firms
U.S. STOCKS ON THE MOVE-Spotify, Ulta Beauty, SPAR Group
U.S. STOCKS ON THE MOVE-Lenz Therapeutics, Intel, ARCA Biopharma
Aldeyra Therapeutics rises after Oppenheimer upgrades to 'outperform'
Brief: Aldeyra Therapeutics Announces Clinical Development Plan For Resubmission Of New Drug Application For Reproxalap
Aldeyra Therapeutics Inc reports results for the quarter ended in December - Earnings Summary
Brief: Aldeyra Therapeutics Announces Advancement of RASP Platform in Systemic and Retinal Inflammatory Diseases
Aldeyra Therapeutics rises as AbbVie extends option agreement for eye disease drug
Commercialization, License Deal
U.S. STOCKS ON THE MOVE-Rockwell Automation, Crinetics Pharmaceuticals, TransUnion
U.S. STOCKS ON THE MOVE-Arvinas, FMC Corp, Wave Life Science
U.S. STOCKS ON THE MOVE-Enphase, Boeing, Kenvue
Brief: Aldeyra Therapeutics Announces Statistically and Clinically Significant Improvement from Baseline in Phase 2 Clinical Trial of ADX‑629 in Patients with Atopic Dermatitis
Aldeyra rises on positive study data for skin disease drug
Aldeyra Therapeutics' skin disease drug succeeds in mid-stage study (updated)
Aldeyra Therapeutics' eczema drug succeeds in mid-stage study
U.S. RESEARCH ROUNDUP-Argenx SE, Avalonbay Communities, Cooper Companies